We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Trial record 15 of 80 for:    Recruiting, Not yet recruiting, Available Studies | "Cholestasis"

Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00738101
Recruitment Status : Recruiting
First Posted : August 20, 2008
Last Update Posted : July 14, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
To provide a mechanism for critically ill infants with parenteral nutrition (PN) associated cholestasis to receive Omegaven for compassionate use situations for which there are no satisfactory alternative treatments.

Condition or disease Intervention/treatment
Cholestasis Cholestasis of Parenteral Nutrition Drug: Omegaven

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
Study Start Date : September 2008
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : June 2018
Arms and Interventions

Arm Intervention/treatment
Experimental: 1
Drug: Omegaven
Drug: Omegaven
Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
Other Name: Omega-3 enriched fat emulsion

Outcome Measures

Primary Outcome Measures :
  1. Safety analysis will include all subjects who receive at least one dose of study drug [ Time Frame: Maximum 5 years ]
    Adequacy of growth parameters and resolution of cholestasis

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be greater than 14 days old and less than 5 years old
  • Conjugated bilirubin greater than 2 mg/dL.
  • Be expected to require intravenous nutrition for at least an additional 28 days

Exclusion Criteria:

  • Have a congenitally lethal condition (e.g. Trisomy 13).
  • Have clinically severe bleeding not able to be managed with routine measures.
  • Have evidence of a viral hepatitis or primary liver disease as the primary etiology of their cholestasis.
  • Have other health problems such that survival is extremely unlikely even if the infant's cholestasis improves.

Home Use of Omegaven®:

In order for a subject to receive the Omegaven® at home through a home health care agency, subjects will first be required to be admitted to Texas Children's Hospital for 72 hours in initiate the administration of the Omegaven®. This will allow time for observation of any unexpected side effects and for parents to be provided education on home TPN and Omegaven®.

If a subject has already received Omegaven® either at TCH or at another hospital, they will not be required to be admitted for the 72 hour inpatient admission prior to starting Omegaven® at home. Parent training will occur during the previous hospital admission and will continue through the TCH Pediatric Intestinal Rehabilitation Clinic.

Outpatient Monitoring:

After the initial evaluation by the TCH Pediatric Intestinal Rehabilitation Clinic physicians, subjects will return to the clinic for routine follow-up. Subjects will be asked to return to the clinic every 2 weeks for the first 2 months of treatment. Thereafter, subjects will return to the clinic on a monthly basis, or as directed by the clinic team.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00738101

Contact: Murali Premkumar, MD 8328267980 premkuma@bcm.edu
Contact: Laura Gollins, RD 8328263639 laromig@texaschildrens.org

United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Murali Premkumar, MD    832-826-7980    premkuma@bcm.edu   
Sub-Investigator: Beth A Carter, MD         
Sub-Investigator: Amy B Hair, MD         
Principal Investigator: Murali Premkumar, MD         
Texas Children's Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Laura Romig, MBA, RD    832-826-3639    laromig@texaschildrens.org   
Sub-Investigator: Beth A Carter, MD         
Sub-Investigator: Amy B Hair, MD         
Principal Investigator: Murali Premkumar, MD         
Sponsors and Collaborators
Baylor College of Medicine
Boston Children’s Hospital
Principal Investigator: Murali Premkumar, MD Baylor College of Medicine
More Information


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Muralidhar Premkumar, Assistant Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00738101     History of Changes
Other Study ID Numbers: H-23365
First Posted: August 20, 2008    Key Record Dates
Last Update Posted: July 14, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Please see the IPD sharing section below.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)

Keywords provided by Muralidhar Premkumar, Baylor College of Medicine:
Liver damage

Additional relevant MeSH terms:
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases